Literature DB >> 16865573

Liver transplantation in the MELD era: a single-center experience.

Mankanwal Sachdev1, Jose L Hernandez, Pratima Sharma, David D Douglas, Thomas Byrne, M Edwyn Harrison, David Mulligan, Adyr Moss, Kunam Reddy, Hugo E Vargas, Jorge Rakela, Vijayan Balan.   

Abstract

Model for Endstage Liver Disease (MELD) score has been used to allocate organs since February 2002. This policy allocates organs to candidates with regard to severity of their underlying liver disease except in the case of hepatocellular carcinoma (HCC) patients. The purpose of this study was to determine the impact of MELD on waiting times, dropout rates, and transplantation rates in all patients awaiting liver transplantation at our center. The records of all patients listed for liver transplantation between May 28, 1999, and February 27, 2004, at the Mayo Clinic, Scottsdale, Arizona, were reviewed. Candidates were grouped by two time periods as pre-MELD or post-MELD based on date of MELD implementation (February 27, 2002). The incidence of deceased donor liver transplantation (DDLT), waiting time to DDLT, dropout rate from the waiting list because of clinical deterioration or death, and survival while waiting for or after DDLT were determined for each group. Three hundred fifty-one patients were listed for liver transplantation (195 pre-MELD, 156 post-MELD) during the study period. HCC patients had an improved rate of transplantation after MELD (pre-MELD, 1.39 persons per year; post-MELD, 3.48 persons per year). In all groups, with the exception of hepatitis C virus, the transplantation rates were the same for both categories. The hepatitis C virus group also had improved transplantation rates in the post-MELD period. HCC candidates under the new allocation policy have an increased incidence of DDLT in our institution. However, this has not disadvantaged patients with non-HCC diagnoses. Thus, the new MELD-based allocation policy has benefited all candidates by allowing more timely transplants.

Entities:  

Mesh:

Year:  2006        PMID: 16865573     DOI: 10.1007/s10620-006-8011-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  12 in total

1.  MELD and PELD: application of survival models to liver allocation.

Authors:  R H Wiesner; S V McDiarmid; P S Kamath; E B Edwards; M Malinchoc; W K Kremers; R A Krom; W R Kim
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

2.  Should hepatomas be treated with hepatic resection or transplantation?

Authors:  J Yamamoto; S Iwatsuki; T Kosuge; I Dvorchik; K Shimada; J W Marsh; S Yamasaki; T E Starzl
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

3.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.

Authors:  M Malinchoc; P S Kamath; F D Gordon; C J Peine; J Rank; P C ter Borg
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

Review 4.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

5.  Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis.

Authors:  G Otto; U Heuschen; W J Hofmann; G Krumm; U Hinz; C Herfarth
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

6.  Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome.

Authors:  G B Klintmalm
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

7.  Liver transplantation for hepatocellular carcinoma: the MELD impact.

Authors:  Pratima Sharma; Vijayan Balan; Jose L Hernandez; Ann M Harper; Erick B Edwards; Hector Rodriguez-Luna; Thomas Byrne; Hugo E Vargas; David Mulligan; Jorge Rakela; Russell H Wiesner
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

8.  Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD.

Authors:  Paul H Hayashi; James F Trotter; Lisa Forman; Marcelo Kugelmas; Tracy Steinberg; Paul Russ; Michael Wachs; Thomas Bak; Igal Kam; Gregory T Everson
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

9.  A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.

Authors:  Francis Y Yao; Nathan M Bass; Bev Nikolai; Raphael Merriman; Timothy J Davern; Robert Kerlan; Nancy L Ascher; John P Roberts
Journal:  Liver Transpl       Date:  2003-07       Impact factor: 5.799

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  3 in total

1.  Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation.

Authors:  Cynthia Tsien; Ari Garber; Arvind Narayanan; Shetal N Shah; David Barnes; Bijan Eghtesad; John Fung; Arthur J McCullough; Srinivasan Dasarathy
Journal:  J Gastroenterol Hepatol       Date:  2014-06       Impact factor: 4.029

2.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

3.  Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients.

Authors:  Christian E Oberkofler; Philipp Dutkowski; Reto Stocker; Reto A Schuepbach; John F Stover; Pierre-Alain Clavien; Markus Béchir
Journal:  Crit Care       Date:  2010-06-15       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.